Heidi Anderson Hupe brings more than 5 years of board and advisory work with PE and VC-backed portfolio companies. As a Board Member at Solis Mammography (Madison Dearborn Partners) from 2021 to 2025 until the sale to Towerbrook Capital, Heidi brought valuable commercial strategy expertise to complement the organization's financial and clinical leadership. She served on the Quality and Compliance Committee where she provided strategic governance that enhanced the company's market position through exceptional clinical outcomes and customer experience. She played an active role in supporting the commercial launch of Mammo Heart, an AI-powered initiative to detect cardiovascular disease in women through their screening mammograms—an early example of applying AI to unlock new clinical value from existing diagnostic infrastructure.

Heidi's executive career spans healthcare, technology, consumer and B2B media organizations. Adept at P&L management, Heidi brings a blend of strategic vision, commercial acumen, and market insight. As President and Chief Growth Officer at Nox Health, a global leader in sleep care, she built and led a 30-person commercial and operations team driving enterprise business representing 40% ($30M) of company revenues. Her leadership was instrumental in securing a $60M strategic capital investment and achieving 20% growth across key enterprise accounts including AT&T, Coca-Cola, and Delta Airlines. Heidi served on the Livongo executive team during Teladoc’s acquisition of the business and formation of a comprehensive platform for virtual care. She directed a 130-person organization managing a $350M portfolio, maintaining a 95% client retention rate, and driving $30M in cross-sell revenue.

Her governance experience was shaped during Time Inc.'s preparation for public sale, where she led the $175M healthcare vertical P&L while company revenues grew from $1B to $1.8B. At Outcome Health, she was recruited by investors (Google, Goldman and Pritzker) to orchestrate a comprehensive company turnaround, navigating complex legal, regulatory and compliance processes, driving 60% YOY revenue growth and enabling the successful recapitalization that positioned the company for acquisition. Heidi offers valuable insight for boards and companies navigating capital raises, M&A activities, and significant organizational transformations.

Heidi currently serves as Chief Growth Officer at Radical Health (AI Oncology), where she is building the go-to-market and reimbursement infrastructure to translate breakthrough AI clinical innovation into real-world adoption across payors, employers, and oncology care pathways—bridging the critical gap between clinical validation and commercial scale. She also advises AliveCor Heart Health (Khosla Ventures). Her broader advisory portfolio includes early-stage health and technology companies with capital raises, product development, and go-to-market strategy, including Adesso Health (women’s cardio health tech) and AI-based health tech companies in stealth mode. A consistent thread across her work: partnering with international founders - including at Nox Health (Iceland) and Radical Health (Denmark/UK) - to build and scale US commercial infrastructure from the ground up.

Known as a visionary strategist, exceptional people leader, technology evangelist and experienced operator, Heidi brings a distinctive leadership philosophy to her board service. She excels at identifying connections between business challenges and opportunities, approaching governance with strategic resourcefulness and innovative problem-solving. Her leadership ethos centers on the belief that "transformational success emerges when creative vision unites with disciplined execution, empowering teams to turn breakthrough ideas into reality.”